Elite Pharmaceuticals, Inc.
ELTP · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $465 | $155 | $29 | $35 |
| - Cash | $11 | $7 | $8 | $9 |
| + Debt | $11 | $12 | $4 | $3 |
| Enterprise Value | $464 | $160 | $25 | $30 |
| Revenue | $84 | $57 | $34,155 | $32 |
| % Growth | 48.4% | -99.8% | 105,767.6% | – |
| Gross Profit | $40 | $26 | $16,594 | $15 |
| % Margin | 47.7% | 46.5% | 48.6% | 45.9% |
| EBITDA | $3 | $3 | $6 | $6 |
| % Margin | 3.4% | 4.5% | 0% | 20.1% |
| Net Income | -$4 | $20 | $4,410 | $9 |
| % Margin | -5.1% | 35.5% | 12.9% | 27.6% |
| EPS Diluted | -0.004 | 0.02 | 4.35 | 0.007 |
| % Growth | -120.3% | -99.5% | 58,683.8% | – |
| Operating Cash Flow | $7 | -$3 | $3 | $7 |
| Capital Expenditures | -$3 | -$1 | -$6 | -$0 |
| Free Cash Flow | $5 | -$4 | -$2 | $6 |